JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma
Mené sur 514 patients atteints d'un carcinome épidermoïde de l'oesophage de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, du toripalimab en combinaison avec une chimiothérapie par paclitaxel et cisplatine
The phase III JUPITER-6 trial showed superior progression-free survival and overall survival for toripalimab plus chemotherapy, compared with chemotherapy alone, in previously untreated patients with advanced esophageal squamous cell carcinoma. This provides solid evidence that immune checkpoint inhibitors are key drugs for the first-line treatment of advanced esophageal squamous cell carcinoma.
Cancer Cell , commentaire, 2021